Pfizer Inc (PFE)

Interest coverage

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Earnings before interest and tax (EBIT) (ttm) US$ in thousands 3,213,000 12,226,000 24,152,000 33,157,000 35,939,000 34,360,000 33,228,000 28,461,000 25,124,000 22,295,000 15,619,000 12,895,000 10,978,000 7,698,000 17,367,000 17,609,000 18,183,000 18,775,000 12,129,000 12,455,000
Interest expense (ttm) US$ in thousands 2,209,000 1,834,000 1,450,000 1,235,000 1,239,000 1,242,000 1,256,000 1,279,000 1,293,000 1,324,000 1,344,000 1,395,000 1,449,000 1,517,000 1,581,000 1,603,000 1,574,000 1,529,000 1,430,000 1,367,000
Interest coverage 1.45 6.67 16.66 26.85 29.01 27.67 26.46 22.25 19.43 16.84 11.62 9.24 7.58 5.07 10.98 10.99 11.55 12.28 8.48 9.11

December 31, 2023 calculation

Interest coverage = EBIT (ttm) ÷ Interest expense (ttm)
= $3,213,000K ÷ $2,209,000K
= 1.45

Pfizer Inc.'s interest coverage ratio has shown a strong trend of improvement over the past eight quarters, indicating the company's ability to comfortably meet its interest obligations from its operating profits. The ratio has significantly increased from 8.68 in Q4 2022 to 42.85 in Q1 2023, reflecting a substantial enhancement in the company's financial stability and creditworthiness. This upward trajectory is a positive sign for investors and creditors, as it suggests a lower risk of default due to the company's solid ability to generate enough earnings to cover its interest expenses. Overall, Pfizer Inc.'s interest coverage has exhibited a robust performance, showcasing sound financial health and efficient management of debt obligations.


Peer comparison

Dec 31, 2023


See also:

Pfizer Inc Interest Coverage (Quarterly Data)